

Jun Zhao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7881984/publications.pdf>

Version: 2024-02-01

75
papers

4,532
citations

393982

19
h-index

114278

63
g-index

83
all docs

83
docs citations

83
times ranked

5435
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 1819-1830.	6.3	2,347
2	Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIB to IV Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2653-2659.	0.8	281
3	Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer (Camel): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 305-314.	5.2	277
4	Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 709.	3.4	185
5	Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2753-2761.	0.8	123
6	Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 1324-1330.	3.2	100
7	Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. , 2020, 8, e000437.		86
8	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 892-901.	3.2	80
9	Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 1296-1304.	3.2	79
10	Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. <i>Oncotarget</i> , 2016, 7, 20810-20824.	0.8	73
11	Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells. <i>Clinical Cancer Research</i> , 2019, 25, 5049-5060.	3.2	66
12	First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2022, 63, 536-542.	2.8	56
13	Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). <i>Journal of Thoracic Oncology</i> , 2017, 12, 1766-1778.	0.5	51
14	Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel Ca_v1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2148-2158.	3.2	45
15	Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1376-1387.	0.5	39
16	A piRNA-like Small RNA Induces Chemoresistance to Cisplatin-Based Therapy by Inhibiting Apoptosis in Lung Squamous Cell Carcinoma. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 6, 269-278.	2.3	37
17	Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study. <i>Journal of Hematology and Oncology</i> , 2020, 13, 37.	6.9	32
18	A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. <i>Lung Cancer</i> , 2020, 147, 259-268.	0.9	31

#	ARTICLE	IF	CITATIONS
19	Patterns and prognosis of locally recurrent rectal cancer following multidisciplinary treatment. <i>World Journal of Gastroenterology</i> , 2012, 18, 7015.	1.4	30
20	Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1403-1414.	0.5	26
21	Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression. <i>BMC Cancer</i> , 2018, 18, 1171.	1.1	22
22	A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database. <i>BMC Cancer</i> , 2020, 20, 666.	1.1	22
23	ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy. <i>Thoracic Cancer</i> , 2019, 10, 2088-2095.	0.8	20
24	Tumor regression grades: Potential outcome predictor of locally advanced rectal adenocarcinoma after preoperative radiotherapy. <i>World Journal of Gastroenterology</i> , 2015, 21, 1851.	1.4	18
25	Ectopic Cushing syndrome in small cell lung cancer: A case report and literature review. <i>Thoracic Cancer</i> , 2017, 8, 114-117.	0.8	17
26	Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation. <i>Clinical Lung Cancer</i> , 2020, 21, e258-e260.	1.1	17
27	Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database. <i>Frontiers in Oncology</i> , 2020, 10, 626.	1.3	17
28	Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification. <i>Translational Lung Cancer Research</i> , 2021, 10, 981-994.	1.3	17
29	Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. <i>Annals of Translational Medicine</i> , 2021, 9, 33-33.	0.7	16
30	Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer. <i>Cancer Letters</i> , 2019, 440-441, 180-188.	3.2	15
31	Survival comparison of right and left side non-small cell lung cancer in stage IIIA patients: A Surveillance Epidemiology and End Results (SEER) analysis. <i>Thoracic Cancer</i> , 2019, 10, 459-471.	0.8	14
32	Analysis of BIM (BCL2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2014, 5, 509-516.	0.8	13
33	Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2017, 29, 553-560.	0.7	13
34	Analysis of MET kinase domain rearrangement in NSCLC. <i>Lung Cancer</i> , 2020, 145, 140-143.	0.9	13
35	Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments. <i>Thoracic Cancer</i> , 2017, 8, 138-146.	0.8	12
36	Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database. <i>Thoracic Cancer</i> , 2019, 10, 1193-1202.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis. <i>BMC Cancer</i> , 2020, 20, 793.	1.1	12
38	Optimal first-line treatment for advanced thymic carcinoma. <i>Thoracic Cancer</i> , 2019, 10, 2081-2087.	0.8	11
39	Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , 2020, 10, 574752.	1.3	11
40	Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1166-1173.	0.8	10
41	Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysis. <i>Thoracic Cancer</i> , 2019, 10, 1788-1797.	0.8	10
42	Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung. <i>Lung Cancer</i> , 2019, 135, 116-122.	0.9	10
43	<i>KRAS</i> oncogene may be another target conquered in non-small cell lung cancer (NSCLC). <i>Thoracic Cancer</i> , 2020, 11, 3425-3435.	0.8	10
44	Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 754-761.	0.8	10
45	The prevalence and real-world therapeutic analysis of Chinese patients with <i>KRAS</i> Mutant Non-Small Cell lung cancer. <i>Cancer Medicine</i> , 2022, 11, 3581-3592.	1.3	10
46	Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib. <i>Frontiers in Oncology</i> , 2020, 10, 729.	1.3	9
47	Community Dynamics of Seed Rain in Mixed Evergreen Broad-leaved and Deciduous Forests in a Subtropical Mountain of Central China. <i>Journal of Integrative Plant Biology</i> , 2007, 49, 1294-1303.	4.1	8
48	Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small cell lung carcinoma. <i>Thoracic Cancer</i> , 2020, 11, 1149-1159.	0.8	8
49	Use of a Combination of CEA and Tumor Budding to Identify High-risk Patients with Stage II Colon Cancer. <i>International Journal of Biological Markers</i> , 2017, 32, 267-273.	0.7	7
50	Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience. <i>Frontiers in Oncology</i> , 2020, 10, 1137.	1.3	7
51	Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma: A Retrospective Analysis of a Multicenter Clinical Study. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 639892.	1.6	7
52	Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy. <i>Thoracic Cancer</i> , 2021, 12, 2825-2828.	0.8	7
53	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018, 7, 428-436.	1.3	7
54	A large-scale, multicentered trial evaluating the sensitivity and specificity of digital PCR versus ARMS-PCR for detecting ctDNA-based EGFR p.T790M in non-small-cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2021, 10, 3888-3901.	1.3	7

#	ARTICLE	IF	CITATIONS
55	A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1507-1515.	1.3	6
56	Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. <i>Frontiers in Oncology</i> , 2021, 11, 709877.	1.3	6
57	A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. <i>Targeted Oncology</i> , 2022, 17, 1-13.	1.7	6
58	Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 2018, 9, 291-297.	0.8	5
59	The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index. <i>Frontiers in Oncology</i> , 2021, 11, 690093.	1.3	5
60	Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations. <i>BMC Cancer</i> , 2021, 21, 1107.	1.1	5
61	Efficacy and safety of bevacizumab in advanced lung adenocarcinoma patients with stable disease after two cycles of first-line chemotherapy: A multicenter prospective cohort study. <i>Thoracic Cancer</i> , 2020, 11, 3641-3644.	0.8	4
62	Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage IIIA non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2021, 13, 1799-1812.	0.6	4
63	Next-generation Sequencing Reveals Age-dependent Genetic Underpinnings in Lung adenocarcinoma. <i>Journal of Cancer</i> , 2022, 13, 1565-1572.	1.2	4
64	Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting. <i>Journal of Thoracic Disease</i> , 2021, 13, 1813-1821.	0.6	3
65	A phase II clinical trial of celecoxib combined with platinum-based regimen as first-line chemotherapy for advanced non-small cell lung cancer patients with cyclooxygenase-2 positive expression. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2009, 21, 1-12.	0.7	2
66	Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1568.	1.3	2
67	Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211124.	1.4	2
68	High expression of ERCC1 is a poor prognostic factor in Chinese patients with non-small cell lung cancer receiving cisplatin-based therapy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2010, 22, 296-302.	0.7	1
69	A phase II study of vorolanib in combination with toripalimab in patients with non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, e21053-e21053.	0.8	1
70	BRAF fusion in lung cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, e21598-e21598.	0.8	1
71	A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2016, 28, 12-8.	0.7	1
72	Separation of tumor cells from bronchoalveolar lavage fluid (BALF) via microgrooves enhanced immiscible filtration assisted by surface tension (ME-IFAST). , 2013, , .		0

#	ARTICLE	IF	CITATIONS
73	Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. <i>Cancer Cell International</i> , 2020, 20, 590.	1.8	0
74	Co-mutation features in treatment-naïve EGFR-mutant lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21616-e21616.	0.8	0
75	Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFR+ non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 1485-1497.	1.1	0